Key Highlights
- Serina Therapeutics shares rocketed 39.45% in extended trading to $1.78 from a closing price of $1.28 during regular hours.
- The biotech firm disclosed a $15 million private placement set to close March 20, plus another $15 million tranche available through April 30.
- Associated warrants could generate an additional $33.3 million, potentially funding operations through late 2027.
- Shares were offered at $2.25 each — representing a 68% premium over the March 17 market close.
- Greg Bailey, a board member with experience in Pfizer’s $11.6B Biohaven and $14B Medivation acquisitions, has been named Co-Chairman.
Serina Therapeutics (SER) experienced a dramatic after-hours rally Wednesday, climbing almost 40% following the biotech company’s announcement of a private placement that could ultimately deliver $63.3 million in capital.
Serina Therapeutics, Inc., SER
The significant price movement occurred after the closing bell, triggered by Serina’s disclosure that an initial $15 million installment will close around March 20, 2026. An additional $15 million tranche is scheduled to close by the end of April.
Shares climbed from their regular-session close of $1.28 — which represented a 4.48% daily decline — to reach $1.78 in after-market activity.
The financing was structured at $2.25 per unit, marking a substantial 68% premium compared to the March 17 closing value. Each unit includes either one share or one pre-funded warrant, along with one-half of a warrant exercisable at $5.00 per share. These warrants carry a four-year exercise window and could contribute another $33.3 million if fully converted, bringing total potential proceeds to $63.3 million.
This capital infusion represents a critical lifeline for the clinical-stage biotechnology firm. According to Serina, the funds should support operations well into the latter half of 2027.
Veteran Investor Elevation Signals Confidence
The financing round was spearheaded by Greg Bailey, M.D., a sitting board member who will assume a new Co-Chairman position alongside current chair Simba Gill, Ph.D.
Bailey arrives with impressive credentials. He was among the early investors in Biohaven Ltd., which Pfizer acquired in 2022 for roughly $11.6 billion, and Medivation, which Pfizer purchased in 2016 for $14 billion.
This proven track record resonated with market participants. When a figure like Bailey not only participates but leads a capital raise, it often provides significant validation in the biotechnology investment landscape.
Capital Deployment Strategy
The raised funds will support Serina’s SER-252 registrational study, a Phase 1b clinical trial focused on treating advanced Parkinson’s disease. Patient enrollment is currently underway at clinical sites throughout Australia and the United States.
SER-252 is advancing through the FDA’s 505(b)(2) approval pathway, which CEO Steve Ledger characterized as “capital-efficient.” The company has already administered the first patient dose in this investigation.
Management anticipates that safety information from Cohort 1 will enable progression to Cohort 2 during the third quarter of 2026. Top-line data from the single-ascending dose portion of the study are expected in the first half of 2027.
The therapeutic candidate addresses an estimated 250,000 patients with advanced Parkinson’s disease across the United States and Europe whose conditions remain poorly managed with existing treatment options.
While Wednesday’s after-hours surge generated excitement, SER’s broader performance trajectory tells a more challenging story. The stock has traded between $1.22 and $7.92 over the past year and has dropped 71.11% during that twelve-month span. The company currently carries a market capitalization of merely $13.65 million, and its Relative Strength Index registers at 29.86 — indicating significantly oversold conditions.
SER finished Wednesday’s standard trading session at $1.28, reflecting a 4.48% intraday decline.
